Lilly Says Its Obesity Drug Tops Novo Nordisk’s Oral Pill in Diabetes Trial
PositiveHealth

Lilly has announced that its new obesity drug outperformed Novo Nordisk's oral semaglutide in a recent diabetes trial, showing significant improvements in blood sugar levels and weight loss. This is a big deal because effective treatments for Type 2 diabetes are crucial for millions of people, and Lilly's success could lead to better management options for patients.
— Curated by the World Pulse Now AI Editorial System